Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022 at 06:45 pm EST
Share
Universal Vision Biotechnology Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 911.45 million compared to TWD 669.75 million a year ago. Net income was TWD 206.36 million compared to TWD 134.41 million a year ago. Basic earnings per share from continuing operations was TWD 2.58 compared to TWD 1.68 a year ago. Diluted earnings per share from continuing operations was TWD 2.58 compared to TWD 1.68 a year ago. Basic earnings per share was TWD 2.58 compared to TWD 1.68 a year ago. Diluted earnings per share was TWD 2.58 compared to TWD 1.68 a year ago.
For the nine months, sales was TWD 2,536.33 million compared to TWD 1,894.79 million a year ago. Net income was TWD 606.74 million compared to TWD 411.35 million a year ago. Basic earnings per share from continuing operations was TWD 7.59 compared to TWD 5.15 a year ago. Diluted earnings per share from continuing operations was TWD 7.58 compared to TWD 5.14 a year ago. Basic earnings per share was TWD 7.59 compared to TWD 5.15 a year ago. Diluted earnings per share was TWD 7.58 compared to TWD 5.14 a year ago.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 
